| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Hydroquinone-d6 does not have a specific biological target for therapeutic use. It is an inert analytical standard. Its purpose is to serve as a tracer or internal standard in mass spectrometry (MS) to improve the accuracy and precision of hydroquinone quantification. By adding a known amount of Hydroquinone-d6 to a sample, researchers can correct for variability in sample preparation, injection, and ionization (matrix effects) because the deuterated compound has identical chemical properties to the analyte but a different mass (+6 Da) that can be distinguished by the mass spectrometer.
|
|---|---|
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine is the first deuterated drug to receive Food and Drug Administration approval. This deuterated form of the drug tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease as well as tardive dyskinesia. Ongoing clinical trials suggest that a number of other deuterated compounds are being evaluated for the treatment of human diseases and not merely as research tools.
In vitro, Hydroquinone-d6 is not used as a drug. Its "activity" is its high isotopic purity (98% D) and chemical stability. It is used as a calibrator in analytical chemistry. For LC-MS method development, a known amount (e.g., 10-50 ng/mL) of Hydroquinone-d6 is added to blank plasma, urine, or cell lysate to create a calibration curve. It is used to validate the specificity, linearity, and accuracy of analytical methods. It has no cytotoxic or biological activity in standard cell viability assays (MTT) at the low concentrations used for analysis. |
| ln Vivo |
Deuterated compounds may, in some cases, offer advantages over nondeuterated forms, often through alterations in clearance. Deuteration may also redirect metabolic pathways in directions that reduce toxicities. The approval of additional deuterated compounds may soon follow. Clinicians will need to be familiar with the dosing, efficacy, potential side effects, and unique metabolic profiles of these new entities.
In vivo, Hydroquinone-d6 is not administered therapeutically. It is used as an internal standard for ex vivo analysis. Following exposure to unlabeled hydroquinone, biological samples (blood, urine, tissue) are spiked with Hydroquinone-d6 to quantify the concentration of the parent compound. It is also used in metabolic tracing studies where a mixture of unlabeled and labeled hydroquinone is administered to an animal to study its absorption, distribution, metabolism, and excretion (ADME) properties, leveraging the kinetic isotope effect (KIE) to differentiate endogenous from exogenous compounds. |
| Enzyme Assay |
General protocol for in vitro enzyme/receptor binding (non-cellular): Not applicable for biological binding. For analytical chemistry use: Prepare a calibration curve by spiking blank matrix (e.g., control plasma) with hydroquinone (analyte) at concentrations of 0.1-100 ng/mL. Add a fixed amount of Hydroquinone-d6 (e.g., 10 ng/mL) to each calibrator, standard, and sample as an internal standard. Perform liquid-liquid extraction or solid-phase extraction to isolate the analytes. Inject onto an LC-MS/MS system. Monitor specific mass transitions for hydroquinone (e.g., m/z 111 → 65) and for Hydroquinone-d6 (m/z 117 → 71). Calculate the peak area ratio (analyte/IS) to determine the unknown concentration.
|
| Cell Assay |
General protocol for in vitro cell-based experiments: Not applicable. Hydroquinone-d6 is not used in cell-based assays for biological activity. If testing toxicity, unlabeled hydroquinone is used. However, for uptake studies, cells can be treated with a mixture of hydroquinone and Hydroquinone-d6 (e.g., 10 uM each). After incubation (1-24 h), wash the cells, lyse them, and analyze the lysate by LC-MS/MS. The deuterated standard is used to calculate the extraction efficiency and to quantify the unlabeled hydroquinone inside the cells.
|
| Animal Protocol |
General protocol for in vivo animal experiments: Hydroquinone-d6 itself is not typically dosed to animals as an internal standard (it is added after sampling). However, for an ADME study, administer unlabeled hydroquinone (e.g., 50 mg/kg PO) to rats. Collect blood at time points 0.5, 1, 2, 4, 6, 8, 12, and 24 h. Immediately after collection, spike each plasma sample with 10 ng/mL of Hydroquinone-d6 as an internal standard. Extract plasma and analyze by LC-MS/MS to generate a pharmacokinetic profile. The deuterated standard corrects for any loss of hydroquinone during sample processing. Store the compound at -20degC.
|
| ADME/Pharmacokinetics |
General pharmacokinetic properties: Hydroquinone-d6 itself is not a drug candidate. The unlabeled parent, Hydroquinone, has a molecular weight of 110.11 g/mol and is highly polar. In vivo, it is rapidly absorbed, conjugated in the liver (glucuronidation and sulfation), and excreted renally (t1/2 ~ 2-4 h in rats). The deuterated version is stable and does not undergo isotopic back-exchange under physiological conditions. For storage: Store as a solid at 4degC in a sealed container. It has a melting point of 174-177degC and a boiling point of 285degC.
|
| Toxicity/Toxicokinetics |
General toxicity profile: Hydroquinone-d6 is a labeled chemical standard. At the concentrations used (ng/mL levels), it is non-toxic. However, the unlabeled parent compound hydroquinone is toxic and classified as a potential carcinogen and mutagen. It is an eye, skin, and respiratory irritant. Hydroquinone-d6 shares these hazardous properties, and standard laboratory safety precautions should be taken: wear gloves, a lab coat, and eye protection. Avoid inhalation of dust. It is classified as Acute Tox. 4 (Oral), Carc. 2, Muta. 2, Aquatic Acute 1, and Eye Dam. 1.
|
| Additional Infomation |
Hydroquinone-d6 (CAS 71589-26-9) is a white to off-white solid. It is also known as 1,4-Dihydroxybenzene-d6. The isotopic purity is 98 atom % D. The product is a stable isotope-labeled (SIL) internal standard considered the "gold standard" for quantitative MS applications. It allows for exact mass matching (M+6) for accurate quantification. It is shipped under normal conditions but should be stored in a cool, dry place. It is for research use only.
|
| Molecular Formula |
C6D6O2
|
|---|---|
| Molecular Weight |
116.15
|
| Exact Mass |
116.074
|
| CAS # |
71589-26-9
|
| Related CAS # |
Hydroquinone; 123-31-9
|
| PubChem CID |
11389380
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
54.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1=C(C(=C(C(=C1O[2H])[2H])[2H])O[2H])[2H]
|
| InChi Key |
QIGBRXMKCJKVMJ-UDDMDDBKSA-N
|
| InChi Code |
InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H/i1D,2D,3D,4D/hD2
|
| Chemical Name |
1,2,4,5-tetradeuterio-3,6-dideuteriooxybenzene
|
| Synonyms |
Hydroquinone-d6; Quinol-d6; 1,4-Benzenediol-d6; 1,4-Dihydroxybenzene-d6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.6096 mL | 43.0478 mL | 86.0956 mL | |
| 5 mM | 1.7219 mL | 8.6096 mL | 17.2191 mL | |
| 10 mM | 0.8610 mL | 4.3048 mL | 8.6096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
